Former Euro PR head joins GolinHarris

Share this article:
Former Euro RSCG Life PR head David Catlett has resurfaced as head of GolinHarris’ New York healthcare practice.

Catlett, who joined Euro RSCG Life PR as president from Ketchum last year, becomes EVP for the Chicago-based firm, charged with growing the company’s healthcare practice on the East Coast. He reports to managing director Jennifer Cohan.

Despite its Midwestern base, GolinHarris has amassed a  roster of pharma clients including  Bristol-Myers Squibb; GlaxoSmithKline Consumer Healthcare; Ortho McNeil Neurologics; Shire; and Cord Blood Registry.

Catlett left Euro RSCG Life PR, the company’s product PR practice, in April, around the time the network reorganized under an executive committee following the departure of CEO Jim Metropoulos. In May, the agency spun off its corporate PR practice, Russo Partners, in a buyout, maintaining a referral relationship with the firm.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...